Note 6 - Revenues

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

(

6

) REVENUES:

The Company operates in

one

business segment, which primarily focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where net product revenues exceed

10%

of consolidated net product revenues. The concentration of the Company’s net product revenues within the regions below

may

have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The Company adopted the requirements of ASC

606

on

January 1, 2018

using the modified retrospective method. See Note

1

(g) – Revenue Recognition for additional discussion.

Revenues by product are summarized as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Trappsol Cyclo	$	--	$	16,500	$	166,596	$	330,681
Trappsol HPB		125,944		171,470		305,706		595,139
Trappsol research		57,798		34,436		175,200		102,555
Aquaplex		37,486		188		116,081		17,572
Other		3,252		18,553		8,381		23,342
Total revenues	$	224,480	$	241,147	$	771,964	$	1,069,289

Substantially all of our sales of Trappsol® Cyclo™ for the

nine

months ended

September 30, 2018

and

September 30, 2017

were to a particular customer who exports the drug to South America. There were

no

sales of Trappsol® Cyclo™ to this customer during the

three

months ended

September 30, 2018

and

2017.

Substantially all of our Aquaplex sales are to

one

customer.